Silo Pharma, Inc.
No SEC Form 4 filings for $SILO in the last 30 days.
See all $SILO insider activity →Silo Pharma (SILO) announced that its subsidiary QwikAgents has added support for NVIDIA API keys and Hermes runtime. This allows customers to access NVIDIA's Nemotron models and choose between two runtimes. The company aims to provide flexibility in AI model and runtime selection.
IM Cannabis (IMCC) surged 245% with no clear catalyst, trading between $2.97 and $8.65. XORTX (XRTX) rose 12% on plans for a 2026 FDA application. Silo Pharma (SILO) gained 6.73% after a U.S. patent allowance. Biofrontera (BFRI) increased 5.65% despite no new news, following an FDA approval for Ameluz.
Silo Pharma (SILO) received a U.S. patent allowance for SPC-15, its PTSD treatment. The patent covers compositions and methods for preventing stress-induced behavioral responses. The company's stock closed at $1.72, down 2.27%, and is trading at $1.65 in pre-market.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning SILO (Silo Pharma, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent SILO coverage spans corporate actions, technology and market movers.
The new NVIDIA model support and Hermes runtime broaden QwikAgents' AI offering, potentially attracting more customers and modestly boosting the stock.
Patent allowance strengthens IP position and future commercialization prospects.
Patent allowance strengthens Silo's IP portfolio and may improve future valuation.
The acquisition expands Silo's product portfolio and may boost future revenue streams.
Authorized-share increase can facilitate future equity issuance, potentially diluting existing holders, and may affect near-term capital-structure expectations.
AlphAI scores every news story that mentions SILO with an AI model for sentiment and relevance, and aggregates insider trades from Silo Pharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Silo Pharma (SILO) announced that its subsidiary QwikAgents has added support for NVIDIA API keys and Hermes runtime. This allows customers to access NVIDIA's Nemotron models and choose between two runtimes. The company aims to provide flexibility in AI model and runtime selection.
1 min readIM Cannabis (IMCC) surged 245% with no clear catalyst, trading between $2.97 and $8.65. XORTX (XRTX) rose 12% on plans for a 2026 FDA application. Silo Pharma (SILO) gained 6.73% after a U.S. patent allowance. Biofrontera (BFRI) increased 5.65% despite no new news, following an FDA approval for Ameluz.
2 min readSilo Pharma (SILO) received a U.S. patent allowance for SPC-15, its PTSD treatment. The patent covers compositions and methods for preventing stress-induced behavioral responses. The company's stock closed at $1.72, down 2.27%, and is trading at $1.65 in pre-market.
1 min readSilo Pharma, Inc. (SILO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 18, 2026, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Parkview Consulting LLC (the “Seller”). Pursuant to the Agreement, the Seller agreed to sell, and the Compan
2 min readSilo Pharma, Inc. (SILO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On August 14, 2026, shareholders of Silo Pharma, Inc. (the “Company”) approved an increase to the number of authorized shares of the Company’s common stock, par value $0.0001 (“Common Stock”) from
2 min readIndonesia Stock Exchange (IDX) expanded its High Shareholding Concentration (HSC) list to 51 stocks, adding names including DCII, BYAN, and MORA. The HSC label highlights concentrated ownership and potential liquidity and price sensitivity risks. IDX cited updated methodology and noted regulators are assessing liquidity quality ahead of MSCI review in Nov 2026.
4 min readSilo Pharma (Nasdaq: SILO) said its wholly owned subsidiary QwikAgents was accepted into AMD’s AI Developer Program, gaining access to AMD Developer Cloud credits, tools, and training resources. QwikAgents is developing an enterprise AI agent platform with starter plans from $14 per month, targeting deployment, testing, optimization, benchmarking, and potential training of agent workloads.
3 min readSilo Pharma, Inc. (SILO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 ea029760202ex10-1.htm FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 9, 2026, between Silo Pharma, Inc., a Nevada corporation (the “ Company ”), and each purcha
3 min readSilo Pharma (NASDAQ: SILO) said it entered definitive agreements for a private placement at-the-market under NASDAQ rules to issue and sell 619,965 shares, or pre-funded warrants, plus Series A-3 and short-term Series A-4 warrants. Price was $6.452 per share, with $6.21 exercise price. Gross proceeds are about $4 million, up to $7.7 million if warrants are fully exercised.
2 min readSilo Pharma (Nasdaq: SILO) announced a private placement under Nasdaq at-the-market rules to issue 619,965 shares (or pre-funded warrants) at $6.452 per share, with Series A-3 and short-term Series A-4 warrants exercisable immediately. Gross proceeds are expected at about $4.0M, with up to about $7.7M more if warrants are fully exercised. Proceeds will fund working capital and general corporate purposes.
4 min read
